SCHEMBL1103579

SCHEMBL1103579

c1ccc(-c2ccc3cc(-c4c5ccccc5c(-c5cccc6ccccc56)c5c4cnc4ccccc45)ccc3c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
LMNA P02545 1/20 0.41
RECQL P46063 1/20 0.41
RAB9A P51151 1/20 0.41
MET P08581 2/20 0.39
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
MTOR P42345 1/20 0.39
PIK3CG P48736 1/20 0.39
ESR1 P03372 2/20 0.39
ESR2 Q92731 2/20 0.39
MAPK10 P53779 1/20 0.37
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
TP53 P04637 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103457 0.95 ESR1 (0.42) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL1103566 0.95 MET (0.42) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL1103571 0.95 MAPT (0.40) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL1103580 0.95 MET (0.43) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL1103453 0.95 MET (0.42) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL1103581 0.94 MET (0.42) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL1103563 0.94 MAPT (0.40) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL1103575 0.93 MET (0.46) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL1103558 0.91 MAPT (0.42) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL1103388 0.91 MET (0.44) MAPTSMN1; SMN2NPC1LMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 MAPT 3162/4885SMN1; SMN2 4091/4885NPC1 1582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.